Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy

Sponsor
Helse Stavanger HF
Study ID
NCT05589974
Status
Recruiting
Apply to this trial

Conditions

  • Central Serous Chorioretinopathy

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Verteporfin — DRUG
    Chronic CSC are receiving one treatment before the observation period.

Study Details

Patients with central serous chorioretinopathy (CSC) will be monitored with laser speckle flow graphy (LSFG), swept source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA). The aim is to unveil the flow and pulse wave characteristics of the choroidal circulation in acute CSC and chronic CSC.

Key Dates

Start date
Oct 1, 2022
Status verified
Nov 2023
Primary completion
Dec 31, 2025
Completion
Jul 31, 2026

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Acute
    Patients with acute first attack CSC with subretinal fluid (SRF) on OCT and symptom duration under 4 months.
  • Arm: Chronic
    Patients with chronic CSC, i.e. symptoms and SRF for more than 4 months.

Primary Outcome Measure

Change in mean blur rate [ Time Frame: 6 months ]

Central Contacts

Related Studies